Detail akcie Codexis online

Business Summary: Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Codexis Inc revenues decreased 49% to $70.1M. Net loss increased from $33.6M to $76.2M. Revenues reflect EMEA segment decrease of 59% to $22.9M, APAC segment decrease of 48% to $33.5M. Higher net loss reflects Other expenses net, decrease from $124K (income) to $12.3M (expense), Selling and General Expenses increase of 10% to $46M (expense).